Skip to main content
USA News
 

MASON, Ohio --(BUSINESS WIRE)--Jul. 10, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2019 financial results on Tuesday, July 30, 2019 .

 

The trial is intended to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients with persistent or long-standing persistent atrial fibrillation MASON, Ohio --(BUSINESS WIRE)--Apr. 23, 2019-- AtriCure, Inc.

 

Worldwide revenue of $54.0 million – an increase of 14.8% year over year U.S. revenue of $43.0 million – an increase of 11.9% year over year International revenue of $11.0 million – an increase of 28.1% year over year MASON, Ohio --(BUSINESS WIRE)--Apr. 25, 2019-- AtriCure, Inc.

 

MASON, Ohio --(BUSINESS WIRE)--Apr. 4, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019 .

 

MASON, Ohio --(BUSINESS WIRE)--Feb. 4, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday,

 

MASON, Ohio --(BUSINESS WIRE)--Jan. 7, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and full year 2018 and provided 2019

 

MASON, Ohio --(BUSINESS WIRE)--Apr. 1, 2019-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Needham & Company’s 18 th Annual Healthcare Conference in New

 

MASON, Ohio --(BUSINESS WIRE)--Dec. 13, 2018-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the 37 th Annual J.P.

 

2018 Worldwide revenue of $201 .6 million – an increase of 15.4% year over year 2018 U.S. revenue of $162 .1 million – an increase of 17.2% year over year 2018 International revenue of $39 .5 million – an increase of 8.7% year over year MASON, Ohio --(BUSINESS WIRE)--Feb. 28, 2019-- AtriCure, Inc.

 

Endorsement complements the company’s ongoing commitment to physician education MASON, Ohio --(BUSINESS WIRE)--Feb. 19, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The

 

cryoSPHERE probe launched in United States , designed exclusively for post-operative pain block MASON, Ohio --(BUSINESS WIRE)--Feb. 12, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced

 

Trial will evaluate the safety and effectiveness of AtriCure’s cryoICE ® Ablation System for the treatment of persistent and long-standing persistent atrial fibrillation in open concomitant cardiac surgery MASON, Ohio --(BUSINESS WIRE)--Feb. 5, 2019-- AtriCure, Inc.

 

MASON, Ohio --(BUSINESS WIRE)--Oct. 11, 2018-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018 .

 

MASON, Ohio --(BUSINESS WIRE)--Oct. 4, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced the pricing of its underwritten offering of 2.5 million shares of its common stock at a price to

 

MASON, Ohio --(BUSINESS WIRE)--Oct. 3, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced it has commenced an underwritten public offering of 2.5 million shares of its common stock